Table 1 Quality description of the included studies according to the criteria of study population (inception cohort, description of source population, description of inclusion/exclusion criteria), follow-up ARRY-438162 (at least 12 months, drop outs, description of completers and drop outs, design of the study), treatment (standardized), prognostic factors (relevant, valid, presented), outcome (relevant, valid, presented), analysis
(univariate, multivariate), and the quality score (good ≥ 13, 9 ≤ moderate ≤ 12) (See also “”Appendix B”" for definitions) Primary author year of publication Study population Follow-up Treatment Prognostic factors Outcome Analysis Quality Incept Pop Incl Year %Out Descrp Dsgn Stnd Rlvnt Valid Pres Rlvnt Valid Pres Uni Multi Sum Good quality Gross et al. (2009) 0 1 1 1 0 0 1 1 1 1 find more 1 1 1 1 1 1 13 Moderate quality Bachman et al. 2003) 0 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 12 Branton et al. (2010) 0 1 1 1 1 1 1 0 1 1 0 1 1 0 1 1 12 Cheng and Cheng (2010) 0 1 1 0 1 0 1 0 1 1 1 1 1 1 1 1 12 Fishbain et al. (1999) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 0 0 11 Gouttebarge et al. (2009a) 1 1 1 1 1 1 1 0
0 0 0 1 1 1 1 0 11 Gross et al. (2006) 0 1 1 1 0 0 1 0 0 0 0 1 1 1 1 1 9 Hazard et al. (1991) 0 1 1 1 0 1 1 1 1 1 1 1 1 1 0 0 12 Kool et al. (2002) 0 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 12 Lechner et al. (2008)
0 1 1 0 1 1 1 1 0 0 0 1 1 1 0 0 9 Matheson et al. (2002) 0 1 1 0 1 0 1 0 1 1 0 1 1 1 1 1 11 Mayer et al. (1986) 0 1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Strand et al. (2001) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 0 12 Vowles et al. (2004) 0 0 1 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Sum score 1 17 17 13 12 8 18 9 15 15 13 18 18 17 11 9 Characteristics of the studies The 18 studies reported on 4,113 participants (median = 147, IQR = 152, range 30–650) (Table 2). Ten studies reported on patients with low back pain, six studies L-gulonolactone oxidase in patients with musculoskeletal disorders (MSDs) in general, and in one study on patients with upper extremity disorders. In one study, the type or region of the MSDs was not specified. In at least 78% of the studies (14/18), the MSDs were described as chronic. Seventeen of the 18 studies took place in a rehabilitation setting and one in an occupational setting. The buy ICG-001 median follow-up period of the studies is 12 months (IQR = 3, range 3–30 months).